Human CD30: Structural implications from epitope mapping and modeling studies

Journal of Molecular Recognition

Volumn 16, Issue 1, 2003, Pages 28-36

  Dong, Liying ^a,b   Hülsmeyer, Martin ^a,c   Dürkop, Horst ^a   Hansen, Hinrich P ^d   Schneider Mergener, Jens ^a   Ziegler, Andreas ^a   Uchanska Ziegler, Barbara ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Jerini AG   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d NONE

Author keywords

CD30; Epitope mapping; Homology modeling; Monoclonal antibody; Peptide array

Indexed keywords

ALANINE; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD30; CELL LINE; EPITOPE MAPPING; HUMANS; MODELS, MOLECULAR; PEPTIDES; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY;

PHRAGMITES; ZIZIPHUS MAURITIANA;

EID: 12244311477     PISSN: 09523499     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmr.605     Document Type: Article

References (34)

1. Amakawa R, Hakem A, Kundig TM, Matsuyama T, Simard JJ, Timms E, Wakeham A, Mittruecker HW, Griesser H, Takimoto H, Schmits R, Shahinian A, Ohashi P, Penninger JM, Mak TW. 1996. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice. Cell 84: 551-562.
2. Armitage RJ. 1997. CD153 Workshop Report. In Leucocyte Typing VI, Kishimoto T et al. (eds). Garland Publishing, New York; 98-100.
3. Bodmer JL, Schneider P, Tschopp J. 2002. The molecular architecture of the TNF superfamily. Trends Biochem. Sci. 27: 19-26.
4. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. 2000. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 288: 2351-2354.
5. Dürkop H, Latza U, Hummel M, Eitelbach F, Seed B, Stein H. 1992. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68: 421-427.
6. Dürkop H, Oberbarnscheidt M, Latza U, Bulfone-Paus S, Hirsch B, Pohl T, Krause H, Hummel M, Stein H. 2000. The restricted expression pattern of the Hodgkin's lymphoma-associated cytokine receptor CD30 is regulated by a minimal promoter. J. Pathol. 192: 182-193.
7. Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Dürkop H, Aversa F, Corneli P, Pizzolo G. 1992. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. Lancet 339: 1195-1196.
8. Frank R. 1992. Spot synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support. Tetrahedron 48: 9217-9232.
9. Franke AC, Jung D, Ellis TM. 2000. Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies. Hybridoma 19: 43-48.
10. Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Lee YHW, Dürkop H, Engelmann H, Scheurich P, Wajant H, Strasser A. 1999. Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 18: 3034-3043.
11. Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B, Kloft M, Pfreundschuh M. 1997. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89: 2042-2047.
12. Hemmann S, Ziegler A, Uchanska-Ziegler B. 2002. Expression of the cystein-rich extracellular domain of CD30 in Drosophila melanogaster S2 cells and selection of CD30-specific human single-chain Fv antibodies from a phage display library. In Leucocyte Typing VII, Mason D et al. (eds). Oxford University Press, New York; 463-466.
13. Horie R, Watanabe T. 1998. CD30: expression and function in health and disease. Sem. Immunol. 10: 457-470.
14. Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, Sterry W, Parwaresch RM, Lemke H. 1995. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int. J. Cancer 60: 539-544.
15. Jones TA, Kjeldgaard M. 1997. Electron-density map interpretation. Meth. Enzymol. 277: 173-208.
16. Klussmann S, Nolte A, Bald R, Erdmann VA, Furste JP. 1996. Mirror-image RNA that binds D-adenosine. Nat. Biotechnol. 14: 1112-1115.
17. Kramer A, Schneider-Mergener J. 1998. Synthesis and screening of peptide libraries on continuous cellulose membrane supports. Methods Mol. Biol. 87: 25-39.
18. Kramer A, Reineke U, Dong L, Hoffmann B, Hoffmuller U, Winkler D, Volkmer-Engert R, Schneider-Mergener J. 1999. Spot synthesis: observations and optimizations. J. Pept. Res. 54: 319-327.
19. Locksley RM, Killeen N, Lenardo MJ. 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501.
20. Lotze MT, Zola H. 1997. CD30 Workshop Report. In Leucocyte Typing VI, Kishimoto T et al. (eds). Garland Publishing, New York; 489-491.
21. Muta H, Boise LH, Fang L, Podack ER. 2000. CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis. J. Immunol. 165: 5105-5111.
22. Naismith JH, Sprang SR. 1998. Modularity in the TNF-receptor family. Trends Biochem. Sci. 23: 74-79.
23. Naismith JH, Devine TQ, Kohno T, Sprang SR. 1996. Structures of the extracellular domain of the type I tumor necrosis factor receptor. Structure 4: 1251-1262.
24. Nolte A, Klussmann S, Bald R, Erdmann VA, Furste JP. 1996. Mirror-design of L-oligonucleotide ligands binding to L-arginine. Nat. Biotechnol. 14: 1116-1119.
25. Pallesen G, Hamilton-Dutoit SJ. 1988. Ki-1 (CD30) antigen is regularly expressed by tumor cells of embryonal carcinoma. Am. J. Pathol. 133: 446-450.
26. Peitsch MC. 1996. ProMod and Swiss-Model: Internet-based tools for automated comparative protein modeling. Biochem. Soc. Trans. 24: 274-279.
27. Qi SY, Groves JT, Chakraborty AK. 2000. Synaptic pattern formation during cellular recognition. Proc. Natl Acad. Sci. USA 98: 6548-6553.
28. Reineke U, Sabat R, Welfle H, Yolk HD, Schneider-Mergener J. 1999a. Synthesis of a mimic of a discontinuous binding site on interleukin-10. Nat. Biotech. 17: 271-275.
29. Reineke U, Kramer A, Schneider-Mergener J. 1999b. Knowledge-and library-based mapping of discontinuous protein-protein-interactions by spot synthesis. Curr. Top. Microbiol. Immunol. 243: 23-36.
30. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, Diehl V. 1982. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299: 65-67.
31. Schwarting R, Gerdes J, Durkop H, Falini B, Pileri S, Stein H. 1989. Ber-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope. Blood 74: 1678-1689.
32. Siegmund T, Armitage N, Wicker LS, Peterson LB, Todd JA, Lyons PA. 2000. Analysis of the mouse CD30 gene: a candidate for the NOD mouse type 1 diabetes locus Idd9.2. Diabetes 49: 1612-1616.
33. Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, Gatter K, Falini B, Delsol G, Lemke H. 1985. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 66: 848-858.
34. Wang JH, Smolyar A, Tan K, Liu JH, Kim M, Sun ZY, Wagner G, Reinherz EL. 1999. Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counter-receptors. Cell 97: 791-803.